QQ客服 官方微博 反馈留言

	Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk
	Peng, Mei; Huang, Yanjun; Tao, Ting; Peng, Cai-Yun; Su, Qiongli; Xu, Wanjun; Darko, Kwame Oteng; Tao, Xiaojun; Yang, Xiaoping*
刊名	SCIENTIFIC REPORTS
	2016
卷号	6页码:28611
ISSN号	2045-2322
DOI	10.1038/srep28611
URL标识	查看原文
WOS记录号	WOS:000378356900001
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/5706248
专题	湖南中医药大学
作者单位	1.[Huang, Yanjun 2.Xu, Wanjun 3.Tao, Xiaojun 4.Su, Qiongli 5.Darko, Kwame Oteng 6.Yang, Xiaoping 7.Peng, Cai-Yun 8.Peng, Mei 9.Tao, Ting] Hunan Normal Univ, Sch Med, Dept Pharm, Changsha 410013, Hunan, Peoples R China.
推荐引用方式 GB/T 7714	Peng, Mei,Huang, Yanjun,Tao, Ting,et al. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk[J]. SCIENTIFIC REPORTS,2016,6:28611.
APA	Peng, Mei.,Huang, Yanjun.,Tao, Ting.,Peng, Cai-Yun.,Su, Qiongli.,...&Yang, Xiaoping*.(2016).Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.SCIENTIFIC REPORTS,6,28611.
MLA	Peng, Mei,et al."Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk".SCIENTIFIC REPORTS 6(2016):28611.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。